UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person  
Litchfield Caroline  
(Middle) (First) (Last)  
MERCK & CO., INC., 126 EAST LINCOLN AVENUE  
RAHWAY, NJ 07065  

2. Issuer Name and Ticker or Trading Symbol  
Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)  
2/14/2024

4. If Amendment, Date Original Filed (MM/DD/YYYY)  

5. Relationship of Reporting Person(s) to Issuer  
☐ Director ☐ 10% Owner ☐ Officer ☐ Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)  
☐ Individual ☐ Joint ☐ Group

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Secured/Acquired</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>2/14/2024</td>
<td>M</td>
<td>38,291</td>
<td>$58.08</td>
<td>89,199.194</td>
</tr>
<tr>
<td>Common Stock</td>
<td>2/14/2024</td>
<td>S</td>
<td>38,291</td>
<td>$125.5 [2]</td>
<td>50,908.194</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Date</th>
<th>Number of Derivative Securities Beneficially Owned (A) or (D)</th>
<th>Date Exercisable or Expiration Date</th>
<th>Title of Derivative Security (Instr. 5)</th>
<th>Number of Derivative Securities Beneficially Owned Following Report (A) or (D) (Instr. 4)</th>
<th>Price of Derivative Security</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>5/1/2016</td>
<td>38,291 D</td>
<td>38,291</td>
<td>0</td>
<td>0</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:

(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.5000 to $125.5050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(2) Holdings include shares acquired in dividend reinvestment transactions.

(3) Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.


Reporting Owners

Reporting Owner Name / Address  
Litchfield Caroline  

Relationships  
Director 10% Owner Officer Other

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
Signatures

/s/ Kelly E. W. Grez as attorney-in-fact for Caroline Litchfield  2/15/2024

Signature of Reporting Person  Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.